Medicine, Hematology Oncology Division

Grants

Grants per year 1995 2006 2007 2008 2009 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2034

• 425 Active
• 1259 Finished

Grants per year

Search results

• Study of TTP: Incidence Rates and Risk Factors

  Kwaan, H. C. & Kyriacou, D.

  National Heart, Lung, and Blood Institute

  9/9/02 → 8/31/07

  Project: Research project

  • Thrombotic Thrombocytopenic Purpura 100%
  • purpura 92%
  • Case-Control Study 30%
  • risks 30%
  • Incidence 23%

• Research for Adverse Drug-Events and Reports (RADAR)

  Benson III, A. B., Gradishar, W. J., Kwaan, H. C. & Tallman, M. S.

  National Cancer Institute

  9/15/03 → 8/31/07

  Project: Research project

  • drugs 100%
  • Adverse Drug Reaction 72%
  • Drug 22%
  • information 13%
  • cancer 9%

• Prot# 440E-ONC-0047-140: Phz I Dose-Escalation Study to Eval. Max Tolerated Dose, Safety Profile & Bioavailability of Semi-Solid Matrix (SSM) Capsule Formulation of Orally Admin'd Irinotecan Hydrochloride (CPT-11) Given Alone or in Sequence w/ Orally Admi

  Benson III, A. B.

  Pharmacia & Upjohn, Inc.

  6/12/01 → 9/6/07

  Project: Research project

• Targeting aB-Crystallin and the MEK-MEK Pathway in Basal-Like Breast Cancer

  Gradishar, W. J. & Yehiely, F.

  Breast Cancer Research Foundation

  10/1/06 → 9/30/07

  Project: Research project

• 8th Annual Lynn Sage Breast Cancer Symposium

  Gradishar, W. J.

  AstraZeneca Pharmaceuticals LP

  6/8/06 → 9/30/07

  Project: Research project

• 8th Annual Lynn Sage Breast Cancer Symposium

  Gradishar, W. J.

  Sanofi US Services Inc.

  7/5/06 → 9/30/07

  Project: Research project

• Satellite Symposium - Improvement in Management of Bone Metastases (8th Annual Lynn Sage Breast Cancer Symposium)

  Gradishar, W. J.

  Novartis Pharmaceuticals Corporation

  5/22/06 → 9/30/07

  Project: Research project

• Prot# ACZ EGFR 01: A Phase II, Rand, Dbl-Blind, Parallel Design Stdy to Eval ACZONE (dapsone) Gel, 5% As a Trmt for Rash Related to the Human Epidermal Growth Factor Receptor1 (HER1) /Epidermal-Growth-Factor-Receptor(EGFR) Inhibitor Tarceva® (erlotinib)

  Patel, J. D.

  QLT USA, Inc.

  2/8/07 → 9/30/07

  Project: Research project

• American Society of Clinical Oncology (ASCO) 2006 Review

  Gradishar, W. J.

  Millennium Pharmaceuticals, Inc

  6/22/06 → 9/30/07

  Project: Research project

• Intergovernmental Personnel Agreement for P. Thulasiraman

  Platanias, L. C.

  Jesse Brown VA Medical Center

  7/1/06 → 9/30/07

  Project: Research project

• 8th Annual Lynn Sage Breast Cancer Symposium

  Gradishar, W. J.

  Novartis Pharmaceuticals Corporation

  5/27/06 → 9/30/07

  Project: Research project

• Prot# NU 02I5: A Pilot Study of Hepatic Artery Floxuridine (FUDR), Leucovorin (LV), and Dexamethasone (DEX) via Intraarterial Hepatic Catheter by Transcutaneous Subclavian Access as Treatment for Metastatic Colorectal Cancer or Primary Liver Cancer

  Resnick, S. A. & Mulcahy, M. F.

  Smiths Medical MD, Inc.

  9/30/02 → 10/17/07

  Project: Research project

• Prot# NCI R03L1: A Phase 2 Study of OSI 774 (IND# 63383) in Combination with Celecoxib (Celebrex, Pharmacia) as Second-Line Therapy in Advanced Non-Small Cell Lung Cancer (NCI prot# 5416) (Rush prot# Lung 2002-1)

  Patel, J. D., Flaum, L. E., Frankfurt, O. & Zakarija, A.

  Rush University Medical Center, Pfizer Inc.

  3/22/04 → 1/1/08

  Project: Research project

• 8th Annual Lynn Sage Breast Cancer Symposium

  Gradishar, W. J.

  Pfizer Inc.

  8/2/06 → 1/14/08

  Project: Research project

• HoxA10 Function During Myeloid Differentiation

  Eklund, E. A.

  National Cancer Institute

  2/6/02 → 1/31/08

  Project: Research project

  • Myeloid 100%
  • CYBB 85%
  • Nested Gene 71%
  • genes 71%
  • phosphorylation 71%

• Prot# AEG35156-103: An Open-Label Phase I/II Study of XIAP Antisense AEG35156 Administered to Patients with Refractory/Relapsed AML in Combination with Chemotherapy

  Tallman, M. S.

  Aegera Therapeutics Inc.

  3/12/07 → 3/12/08

  Project: Research project

• SPORE in Prostate Cancer: Project 1

  Lee, C., Kuzel, T. M., Rademaker, A. W. & Zhang, Q.

  National Cancer Institute

  6/1/01 → 4/30/08

  Project: Research project

  • cancer 100%
  • prostate 100%
  • spores 88%
  • Prostate Cancer 77%
  • applications 22%

• Biochemical and Genetic Studies of Latent Membrane Pro 2

  Longnecker, R. M. & Ikeda, M.

  National Cancer Institute

  7/1/03 → 4/30/08

  Project: Research project

  • Epstein Barr Virus 100%
  • epstein-barr virus 100%
  • proteins 60%
  • B Lymphocyte 50%
  • lymphocytes 50%

• American Society of Clinical Oncology (ASCO) 2006 Review

  Gradishar, W. J.

  AstraZeneca Pharmaceuticals LP

  5/22/06 → 5/12/08

  Project: Research project

• American Society of Clinical Oncology (ASCO) 2006 Review

  Gradishar, W. J.

  Novartis Pharmaceuticals Corporation

  5/24/06 → 5/12/08

  Project: Research project

• Prot# TPU-S1301: An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 in Combination w/Cisplatin Compared Against 5-FU in Combination w/Cisplatin in Patients w/Advanced Gastric Cancer Previously Untreated w/Chemotherapy for Advanced Disease

  Benson III, A. B.

  Taiho Pharma U.S.A., Inc.

  4/14/04 → 5/30/08

  Project: Research project

• Desmoplastic Reaction and Pancreatic Cancer Progression

  Munshi, H. G.

  National Pancreas Foundation

  6/1/07 → 5/31/08

  Project: Research project

• ECOG E4Z02: Symptom Management Consortium Member (Phase III Randomized Placebo-Controlled Trial to Determine Efficacy of Levocarnitine for Fatigue in Patients with Cancer

  Benson III, A. B.

  Frontier Science and Technology Research Foundation, National Cancer Institute

  4/1/06 → 5/31/08

  Project: Research project

• American Society of Clinical Oncology (ASCO) 2007 Review

  Gradishar, W. J.

  Bayer Corporation

  5/31/07 → 5/31/08

  Project: Research project

• Understanding the Role of NALP11 and NALP7 Genes in Myeloma Glucoccorticoid Resistance

  Ma, S.

  American Society of Clinical Oncology

  7/1/07 → 6/30/08

  Project: Research project